HTB December 2023/January 2024
1 December 2023. Related: Editorial.
2023
i-Base 2024 appeal: support for LGBTQI+ refugees in Kakuma
1 December 2023. Related: Editorial.
14th International Workshop on HIV and Ageing
1 December 2023. Related: Conference reports, Ageing and life expectancy.
Sarcopenia and mitochondrial dysfunction in people living with HIV: the impact of ageing
1 December 2023. Related: Conference reports, Ageing and life expectancy.
Measuring sarcopenia in people living with HIV
1 December 2023. Related: Conference reports, Ageing and life expectancy.
Latest figures published on HIV in the UK: 2023 report
1 December 2023. Related: Special reports, HIV prevention and transmission.
19th EACS (EACS 2023)
1 December 2023. Related: Conference reports.
EACS 2023: HIV cure-related research
1 December 2023. Related: Conference reports, Cure-related research.
EACS 2023: European guidelines fully revised (October 2023)
1 December 2023. Related: Conference reports, Guidelines.
EACS 2023: Prevalence of doravirine drug resistance in large cohort in British Columbia
1 December 2023. Related: Conference reports, Research studies.
EACS 2023: Switching to daily fixed-dose doravirine/islatravir: 96-week results
1 December 2023. Related: Conference reports, Antiretrovirals.
First-line ART drops below US $45 a year for low-income countries
1 December 2023. Related: Antiretrovirals, Treatment access.
EACS 2023: TDF/FTC dual-nuke ART: not supported by ALTAR study
1 December 2023. Related: Conference reports, Treatment strategies.
EACS 2023: EATG video campaign against HIV stigma
1 December 2023. Related: Conference reports, Other news, On the web.
Potential for monthly injectable: nanoformulated tenofovir/3TC/dolutegravir
1 December 2023. Related: Antiretrovirals.
Dolutegravir monotherapy still not recommended: 4-year follow up in early-treated durably suppressed participants
1 December 2023. Related: Treatment strategies.
CD4:CD8 ratio recovery reduces with higher age when starting ART
1 December 2023. Related: Treatment strategies, Basic science and immunology.
CHAI 2023 market report: decline in HIV funding threatens 20 years of progress
1 December 2023. Related: Treatment access.
Modest increase in rate of cardiovascular disease progression during perimenopause for women living with HIV
1 December 2023. Related: Women's health.
Review of US PEPFAR programme highlights continued higher infant mortality
1 December 2023. Related: Paediatric care, Other news.
Oral tenofovir/FTC increases clearance of bNAb VRC01: implications for future research
1 December 2023. Related: PK and drug interactions, HIV prevention and transmission.
HIV guidelines recommend a statin for all people older than 40: new BHIVA document
1 December 2023. Related: Guidelines, Coinfections and complications.
Mpox update: recent publications (2023)
1 December 2023. Related: mpox (monkeypox).
Mpox vaccines still available and recommended in the UK and US
1 December 2023. Related: mpox (monkeypox).
Pricing new gene therapies for sickle-cell: implications for an HIV cure
1 December 2023. Related: Other news.
Our Stories Told By Us: Celebrating the African contribution to the UK HIV response
1 December 2023. Related: Book and film reviews.
Up to 3% of medical research papers are fake
1 December 2023. Related: Other news.
HTB no 12 December 20023 / January2024
1 December 2023. Related: PDFs.
HTB October/November 2023
1 October 2023. Related: Editorial.
Non-technical summary of articles in HTB October 2023
1 October 2023. Related: Editorial.
Uganda report: Increase in LGBTQI+ assaults and human rights violations need urgent activist responses
1 October 2023. Related: Editorial, Special reports, Treatment advocacy, Other news.
12th IAS Conference on HIV Science (IAS 2023): further reports
1 October 2023. Related: Conference reports.
IAS 2023: Lenacapavir studies at IAS: weekly oral dosing and baseline sensitivity in non-clade B settings
1 October 2023. Related: Conference reports, Antiretrovirals.
IAS 2023: LA-CAB/RPV as first-line ART and implementation studies
1 October 2023. Related: Conference reports, Antiretrovirals.
IAS 2023: bNAbs for prevention and cure: antiviral and vaccine-like responses
1 October 2023. Related: Conference reports, Antiretrovirals, HIV prevention and transmission, Cure-related research, Vaccines and microbicides.
IAS 2023: High rates of re-suppression with dolutegravir in the ADVANCE study
1 October 2023. Related: Conference reports, Treatment strategies, Drug resistance.
IAS 2023: Bictegravir use in pregnancy: more data needed
1 October 2023. Related: Conference reports, Pregnancy.
IAS 2023: In-utero tenofovir-based PrEP has no effect on children’s bone mineral density
1 October 2023. Related: Conference reports, Pregnancy, Paediatric care, HIV prevention and transmission.
UK surveys on access to New-Fill for facial lipoatrophy
1 October 2023. Related: Side effects, Lipodystrophy and metabolic complications.
>10% weight gain during first two years of ART linked to double the risk of cardiometabolic disease
1 October 2023. Related: Side effects, Lipodystrophy and metabolic complications.
EU approves cabotegravir as injectable PrEP
1 October 2023. Related: HIV prevention and transmission.
Altered kidney function associated with alcohol and cannabis use by women living with HIV
1 October 2023. Related: Side effects.
Early phase 1 HIV vaccine study launched in the US and South Africa
1 October 2023. Related: Vaccines and microbicides.
Mutations associated with resistance to dapivirine vaginal ring: reported in 7/38 women seroconverting in the open-label HOPE study
1 October 2023. Related: HIV prevention and transmission.
HTB: no. 10/11 (Oct/Nov 2023) PDF download
1 October 2023. Related: PDFs.
Defective HIV proviral particles linked to persistent inflammation and immune activation despite effective ART
1 September 2023. Related: Pathogenesis, Basic science and immunology.
HTB: no. 9 (Sept 2023) PDF download
1 September 2023. Related: PDFs.
HTB September 2023
1 September 2023. Related: Editorial.
12th IAS Conference on HIV Science (IAS 2023): further reports
1 September 2023. Related: Conference reports.
Non-technical summary of articles in HTB September 2023
1 September 2023. Related: Editorial.
IAS 2023: Update to navigating the programme and online access
1 September 2023. Related: Conference reports.
IAS 2023: Metabolic and weight changes using GLP-1 agonists in people living with HIV: need for more data
1 September 2023. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.
IAS 2023: CHAPAS-4 supports better second-line options for children
1 September 2023. Related: Conference reports, Paediatric care.
IAS 2023: Rapporteur summary Track A – basic science
1 September 2023. Related: Conference reports, Cure-related research, Basic science and immunology, Vaccines and microbicides.
IAS 2023: Rapporteur summary Track C – prevention
1 September 2023. Related: Conference reports, HIV prevention and transmission.
IAS 2023: Rapporteur summary Track D – social and behavioural science
1 September 2023. Related: Conference reports, Treatment strategies.
Timing of ART with cryptococcus: Europe and the US cohort data challenged by African RCT data and editorial comment
1 September 2023. Related: Coinfections and complications.
Cannabis does not reduce T cells in people living with HIV
1 September 2023. Related: Pathogenesis, Basic science and immunology.
Peripheral inflammation linked to structural brain changes and reduced blood flow despite suppressive ART
1 September 2023. Related: Coinfections and complications.
Tecovirimat resistance in a person with advanced HIV and delayed ART
1 September 2023. Related: mpox (monkeypox).
Breakthrough HIV infection on PrEP with injectable cabotegravir
6 August 2023. Related: HIV prevention and transmission.
HTB July/August 2023
1 August 2023. Related: Editorial.
Non technical HTB: 11 stories from July/August
1 August 2023. Related: Editorial.
12th IAS Conference on HIV Science (IAS 2023)
1 August 2023. Related: Conference reports.
IAS 2023: Update to navigate the programme and online access
1 August 2023. Related: Conference reports.